Literature DB >> 29063907

Beyond binding: antibody effector functions in infectious diseases.

Lenette L Lu1,2, Todd J Suscovich1, Sarah M Fortune2, Galit Alter1.   

Abstract

Antibodies play an essential role in host defence against pathogens by recognizing microorganisms or infected cells. Although preventing pathogen entry is one potential mechanism of protection, antibodies can control and eradicate infections through a variety of other mechanisms. In addition to binding and directly neutralizing pathogens, antibodies drive the clearance of bacteria, viruses, fungi and parasites via their interaction with the innate and adaptive immune systems, leveraging a remarkable diversity of antimicrobial processes locked within our immune system. Specifically, antibodies collaboratively form immune complexes that drive sequestration and uptake of pathogens, clear toxins, eliminate infected cells, increase antigen presentation and regulate inflammation. The diverse effector functions that are deployed by antibodies are dynamically regulated via differential modification of the antibody constant domain, which provides specific instructions to the immune system. Here, we review mechanisms by which antibody effector functions contribute to the balance between microbial clearance and pathology and discuss tractable lessons that may guide rational vaccine and therapeutic design to target gaps in our infectious disease armamentarium.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29063907      PMCID: PMC6369690          DOI: 10.1038/nri.2017.106

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  200 in total

1.  Clinical care of two patients with Ebola virus disease in the United States.

Authors:  G Marshall Lyon; Aneesh K Mehta; Jay B Varkey; Kent Brantly; Lance Plyler; Anita K McElroy; Colleen S Kraft; Jonathan S Towner; Christina Spiropoulou; Ute Ströher; Timothy M Uyeki; Bruce S Ribner
Journal:  N Engl J Med       Date:  2014-11-12       Impact factor: 91.245

Review 2.  The importance of natural IgM: scavenger, protector and regulator.

Authors:  Michael R Ehrenstein; Clare A Notley
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

3.  Flexibility of human IgG subclasses.

Authors:  K H Roux; L Strelets; T E Michaelsen
Journal:  J Immunol       Date:  1997-10-01       Impact factor: 5.422

4.  Interleukin 10- and Fcgamma receptor-deficient mice resolve Leishmania mexicana lesions.

Authors:  Laurence U Buxbaum; Phillip Scott
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

5.  Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.

Authors:  Stylianos Bournazos; Florian Klein; John Pietzsch; Michael S Seaman; Michel C Nussenzweig; Jeffrey V Ravetch
Journal:  Cell       Date:  2014-09-11       Impact factor: 41.582

6.  FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

Authors:  Wu Zhang; Michael Gordon; Anne M Schultheis; Dong Yun Yang; Fumio Nagashima; Mizutomo Azuma; Heung-Moon Chang; Eva Borucka; Georg Lurje; Andy E Sherrod; Syma Iqbal; Susan Groshen; Heinz-Josef Lenz
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

7.  High affinity allele for the gene of FCGR3A is risk factor for HIV infection and progression.

Authors:  Bhawna Poonia; Gustavo H Kijak; C David Pauza
Journal:  PLoS One       Date:  2010-12-20       Impact factor: 3.240

8.  Systems biology of vaccination for seasonal influenza in humans.

Authors:  Helder I Nakaya; Jens Wrammert; Eva K Lee; Luigi Racioppi; Stephanie Marie-Kunze; W Nicholas Haining; Anthony R Means; Sudhir P Kasturi; Nooruddin Khan; Gui-Mei Li; Megan McCausland; Vibhu Kanchan; Kenneth E Kokko; Shuzhao Li; Rivka Elbein; Aneesh K Mehta; Alan Aderem; Kanta Subbarao; Rafi Ahmed; Bali Pulendran
Journal:  Nat Immunol       Date:  2011-07-10       Impact factor: 25.606

9.  A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus.

Authors:  Ying Wu; MyungSam Cho; David Shore; Manki Song; JungAh Choi; Tao Jiang; Yong-Qiang Deng; Melissa Bourgeois; Lynn Almli; Hua Yang; Li-Mei Chen; Yi Shi; Jianxu Qi; An Li; Kye Sook Yi; MinSeok Chang; Jin Soo Bae; HyunJoo Lee; JiYoung Shin; James Stevens; SeoungSuh Hong; Cheng-Feng Qin; George F Gao; Shin Jae Chang; Ruben O Donis
Journal:  Nat Commun       Date:  2015-07-21       Impact factor: 14.919

10.  Mast cells and company.

Authors:  Friederike Jönsson; Marc Daëron
Journal:  Front Immunol       Date:  2012-02-20       Impact factor: 7.561

View more
  196 in total

Review 1.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

2.  IgM Plasma Cells Reside in Healthy Skin and Accumulate with Chronic Inflammation.

Authors:  R Paul Wilson; Shannon E McGettigan; Van Duc Dang; Anil Kumar; Michael P Cancro; Neda Nikbakht; William Stohl; Gudrun F Debes
Journal:  J Invest Dermatol       Date:  2019-05-30       Impact factor: 8.551

3.  Some antibodies can dampen antiviral defences in people with severe COVID.

Authors:  Matteo Gentili; Nir Hacohen
Journal:  Nature       Date:  2021-03       Impact factor: 49.962

Review 4.  Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA.

Authors:  Kang Chen; Giuliana Magri; Emilie K Grasset; Andrea Cerutti
Journal:  Nat Rev Immunol       Date:  2020-02-03       Impact factor: 53.106

5.  Interferon-α alters host glycosylation machinery during treated HIV infection.

Authors:  Leila B Giron; Florent Colomb; Emmanouil Papasavvas; Livio Azzoni; Xiangfan Yin; Matthew Fair; Alitzel Anzurez; Mohammad Damra; Karam Mounzer; Jay R Kostman; Pablo Tebas; Una O'Doherty; Hiroaki Tateno; Qin Liu; Michael R Betts; Luis J Montaner; Mohamed Abdel-Mohsen
Journal:  EBioMedicine       Date:  2020-08-19       Impact factor: 8.143

6.  Immunoglobulin G structure and rheumatoid factor epitopes.

Authors:  Sheila Lefoli Maibom-Thomsen; Nicole Hartwig Trier; Bettina Eide Holm; Kirsten Beth Hansen; Morten Ib Rasmussen; Anna Chailyan; Paolo Marcatili; Peter Højrup; Gunnar Houen
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

7.  Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination.

Authors:  Carolyn M Boudreau; Wen-Han Yu; Todd J Suscovich; H Keipp Talbot; Kathryn M Edwards; Galit Alter
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

8.  Capsular glycan recognition provides antibody-mediated immunity against tuberculosis.

Authors:  Tingting Chen; Caroline Blanc; Yanyan Liu; Elise Ishida; Sarah Singer; Jiayong Xu; Maju Joe; Elizabeth R Jenny-Avital; John Chan; Todd L Lowary; Jacqueline M Achkar
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

9.  A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma.

Authors:  Elizabeth L McMichael; Brooke Benner; Lakhvir S Atwal; Nicholas B Courtney; Xiaokui Mo; Melanie E Davis; Amanda R Campbell; Megan C Duggan; Kallan Williams; Kyle Martin; Kala Levine; Gonzalo N Olaverria Salavaggione; Tiffany Noel; Akaansha Ganju; Sarvani Uppati; Bonnie Paul; Thomas Olencki; Theodoros N Teknos; Panos Savvides; Susheela Tridandapani; John C Byrd; Michael A Caligiuri; Stephen V Liu; William E Carson
Journal:  Clin Cancer Res       Date:  2019-05-29       Impact factor: 12.531

10.  Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design.

Authors:  Surender Khurana; Supriya Ravichandran; Megan Hahn; Elizabeth M Coyle; Spencer W Stonier; Samantha E Zak; Jason Kindrachuk; Richard T Davey; John M Dye; Daniel S Chertow
Journal:  Cell Host Microbe       Date:  2020-02-12       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.